Quantum engineering of time-separated Raman laser pulses in three-level systems is presented to produce an ultranarrow optical transition in bosonic alkali-earth clocks free from light shifts and with a significantly reduced sensitivity to laser parameter fluctuations. Based on a quantum artificial complex wave-function analytical model and supported by a full density-matrix simulation including a possible residual effect of spontaneous emission from the intermediate state, atomic phase shifts associated with Ramsey and hyper-Ramsey two-photon spectroscopy in optical clocks are derived. Various common-mode Raman frequency detunings are found in which the frequency shifts from off-resonant states are canceled, while their uncertainties at the ${10}^{\ensuremath{-}18}$ level of accuracy are strongly reduced.
Brivudin, ((<i>E</i>)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) can be considered the gold standard for the treatment of varicella-zoster virus (VZV) infections, such as herpes zoster (shingles). It is available for clinical use in most European countries (except for the UK) and over the whole world (except for the US and Canada). Besides VZV its activity spectrum also includes various other herpesviruses, such as herpes simplex virus type 1 (HSV-1). Its activity against VZV and HSV-1 depends on phosphorylation by the virus-encoded thymidine kinase (TK). In its active form (BVDU TP or BVDU 5'-triphosphate), it can act as both substrate and inhibitor of the viral (i.e., HSV-1) DNA polymerase. It has proven to be effective against herpes zoster, including post-herpetic neuralgia (PHN). It is contra-indicated in patients concomitantly treated by 5-fluorouracil (FU), since its degradation product, (<i>E</i>)-5-(2-bromovinyl)uracil, is inhibitory to the catabolism of FU, which may enhance the toxicity of the latter. A new compound, the bicyclic nucleoside analogue (BCNA) Cf-1743, has been described, which is a more potent inhibitor of VZV replication than BVDU and which does not interfere with the catabolism of FU. It is applicable orally, as its 5'-valine ester FV-100 (Fermavir), but has not (yet) been marketed for clinical use.
NF-kappaB (NF-kappaB), the transcription factors of HIV-1, play an important role in triggering HIV transcription. The inhibition of NF-kappaB activation and their signaling pathway offers a potential anti-HIV therapy strategy. This review reports the mode of action of NF-kappaB in triggering HIV-1 transcription and the status of the inhibitors.
No abstract is provided for this article.
